Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11727752 | 0.60 | ALDH1A1 (0.46) | ALDH1A1MAPK1HPGDSMN1; SMN2LMNA | |
| SCHEMBL17727007 | 0.57 | — | — | |
| SCHEMBL15065262 | 0.57 | — | — | |
| SCHEMBL554847 | 0.57 | — | — | |
| SCHEMBL504808 | 0.53 | — | — | |
| SCHEMBL28290533 | 0.53 | — | — | |
| SCHEMBL31182373 | 0.53 | — | — | |
| SCHEMBL27902460 | 0.53 | — | — | |
| SCHEMBL23526578 | 0.51 | — | — | |
| SCHEMBL11724510 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688704-B2 | Azole silane compound, surface treatment solution, surface treatment method, and use thereof | SHIKOKU CHEMICALS CORPORATION (JP) | 2017-06-27 | — | — | US | disclosed |
| US-20160368935-A1 | AZOLE SILANE COMPOUND, SURFACE TREATMENT SOLUTION, SURFACE TREATMENT METHOD, AND USE THEREOF | SHIKOKU CHEMICALS CORPORATION (JP) | 2016-12-22 | — | — | US | disclosed |
| EP-3018137-A1 | AZOLE SILANE COMPOUND, SURFACE TREATMENT SOLUTION, SURFACE TREATMENT METHOD, AND USE THEREOF | Shikoku Chemicals Corporation (JP) | 2016-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368935-A1 | AZOLE SILANE COMPOUND, SURFACE TREATMENT SOLUTION, SURFACE TREATMENT METHOD, AND USE THEREOF | ICAM1, SULT1A1, STIM1 | FBP1 3967/4885ALDH1A1 484/4885MAPK1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.